Respiratory Syncytial Virus News and Research

RSS

Immunocompromised adults show weaker response to RSV vaccines

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity - primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders - do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with normal immune function.

30 Dec 2024

RSV vaccine acceptance grows amidst rising flu concerns

A year after becoming available, vaccines to protect against RSV in newborns and older adults are being more widely accepted by the American public, according to a new Annenberg Public Policy Center (APPC) health survey conducted in November 2024.

23 Dec 2024

New insights into respiratory syncytial virus and prevention strategies

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health concern. Currently, there are no effective medications for RSV, and current treatment focuses on providing supportive care and preventing its spread.

20 Dec 2024

Polypurine hairpins found to effectively halt SARS-CoV-2 replication

A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting the proliferation of the SARS-CoV-2 virus that causes COVID-19.

3 Dec 2024

Reinstating masking curbs hospital viral outbreaks, study confirms

Researchers investigate how changes in hospital policies for SARS-CoV-2 testing and masking have influenced hospital-acquired respiratory viral infections.

1 Dec 2024

KFF Health News' 'What the Health?': Public health and the dairy cow in the room

Public health, one of the more misunderstood concepts in the health world, is about the health of entire populations, rather than individuals.

26 Nov 2024

New approach to stabilize RSV protein could lead to better vaccines

In most people, the lung-infecting pathogens known as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) trigger mild cold-like symptoms. But in infants and seniors, these viruses can cause severe pneumonia and even death.

20 Nov 2024

Study shows RSV’s severe impact on US adults, urging more testing and vaccination

RSV hospitalizations in US adults reached high levels pre-vaccine, especially impacting those 75 and older, underscoring the need for awareness and prevention efforts.

14 Nov 2024

Maternal RSV vaccination timing optimizes newborn immunity through improved antibody transfer

Maternal RSV vaccination enhances antibody transfer to newborns, with optimal transfer efficiency observed when given at least five weeks before delivery.

14 Nov 2024

HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities

Research on HEPA-14 air purifiers in aged care reveals no significant impact on respiratory infections, though initial phase results suggest potential benefits.

13 Nov 2024

Early RSV vaccination in pregnancy provides best protection for newborns

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) - which typically causes mild, cold-like symptoms in most adults but can be deadly for infants - during weeks 32–36 of pregnancy.

11 Nov 2024

Recruitment underway for a clinical trial testing new vaccine against respiratory viruses

Recruitment is underway for a clinical trial testing a vaccine candidate produced with The University of Queensland's molecular clamp technology against life-threatening respiratory viruses.

8 Nov 2024

WHO study names top pathogens in need of new vaccines

A new World Health Organization (WHO) study published today in eBioMedicine names 17 pathogens that regularly cause diseases in communities as top priorities for new vaccine development.

5 Nov 2024

Study highlights importance of RSV vaccination for high-risk populations

Since their introduction last year, researchers have been monitoring the real-world impact of the new respiratory syncytial virus (RSV) vaccines.

28 Oct 2024

Real world data highlights effectiveness of RSV vaccine

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the RSV -- short for respiratory syncytial virus -- vaccine.

18 Oct 2024

Research links NK cells to severe cases of RSV in children

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in young children due to respiratory complications such as bronchiolitis and pneumonia.

12 Oct 2024

WHO report highlights the role of vaccines in reducing antibiotic use

A new report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR).

10 Oct 2024

FAU researchers highlight new vaccination barriers

Vaccines to prevent common and serious infectious diseases have had a greater impact on improving human health than any other medical advance of the 20th century, surpassing even sanitation and potable water. From the global eradication of smallpox in 1980 to the unprecedented development of effective and safe mRNA vaccines for COVID-19, vaccinations have played crucial roles in preventing millions of premature deaths and hospitalizations in adults and children.

8 Oct 2024

Study reveals high effectiveness of flu vaccines in children but highlights challenges with certain subtypes

Study found that influenza vaccination is highly effective in preventing infection and hospitalization in children, though efficacy against certain subtypes like H3N2 remains limited due to small sample sizes.

6 Oct 2024

New insights into the link between respiratory infections and chronic lung diseases

A 3D reconstruction of a mouse lung four days after infection with fluorescent Sendai virus reveals widespread virus presence (red) and active replication (green).

3 Oct 2024